FIELD: immunology.
SUBSTANCE: isolated antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), as well as bispecific antibodies based on them, are proposed. In addition, nucleic acid, an expression vector, a host cell, treatment methods, and a pharmaceutical composition are considered. A method for inhibiting tumor growth or progression, a method for inhibiting metastasis, a method for inducing tumor regression, and a method for producing an antibody are also proposed.
EFFECT: this invention can find further application in the therapy of malignant tumors expressing FLT3.
26 cl, 11 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| ANTIBODY PURIFICATION | 2019 |
|
RU2812161C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF USE OF ANTIBODIES AGAINST HLA-G | 2019 |
|
RU2810326C2 |
